Skip to main content

Fabry Disease Registry & Pregnancy Sub-registry

Recruiting · NCT00196742

Conditions: Fabry Disease

At a glance

Research payments reported, 2025
$1.0M
U.S. investigators named
63
Sites paid
73
Planned or actual enrollment
9,000

About the trial

Sponsor
Genzyme, a Sanofi Company
Dates
Started 2001-07-31; completion 2034-01-31
Results posted
Not yet

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: * To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease; * To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes …

From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $1.0M in research payments for this study in 2025 (192 payments).

Products named: Fabrazyme

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.